AgomAb Therapeutics (NASDAQ:AGMB – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, FiscalAI reports.
AgomAb Therapeutics Stock Performance
AGMB traded down $0.82 during trading on Thursday, hitting $13.50. The stock had a trading volume of 38,634 shares, compared to its average volume of 71,924. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.52 and a current ratio of 6.52. AgomAb Therapeutics has a twelve month low of $8.75 and a twelve month high of $17.82. The business has a 50-day moving average of $12.18.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on AGMB shares. B. Riley Financial initiated coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target on the stock. HC Wainwright assumed coverage on shares of AgomAb Therapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $35.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.
About AgomAb Therapeutics
AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.
AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.
Further Reading
- Five stocks we like better than AgomAb Therapeutics
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
